Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.
News|Articles|January 23, 2026
- Vol.27/No.2
- Volume 27
- Issue 2
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
Author(s)Kyle Doherty
Fact checked by: Cheney Gazzam Baltz
Experts across tumor types share their insights on the notable FDA regulatory decisions of 2025.
Advertisement
Advertisement
In 2025, more than 60 agents and combinations, including biosimilars, earned accelerated, regular, or expanded approvals from the FDA, reshaping the treatment paradigms of multiple disease states and offering additional options for patients.
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
Advertisement
Advertisement